NicOx.... in attesa di..... (13 lettori)

[guly]

potrei farti in elenco infinito di titoli di cac....a, pure nel nasdaq non scherzano....diciamo che non è certo il momento delle biotech....

piu' che non il momento delle biotech ormai si e' capito che sono solo macchine mangiasoldi.il 90% sono create con la scusa della ricerca dei farmaci solo per ingrassare i ceo e i dipendenti che ci lavorano alle spalle di chi ci mette i soldi.sono solo apparati che vengono creati appositamente per fare questo gioco.alla fine chi ci rimette sono sempre i piccoli azionisti mentre chi ci guadagna sono sempre loro.loro non rischiano niente ma guadagnano solo.ormai l'ho ben capito e non ci metto piu' un centesimo.per me possono pure crepare di fame questi bastardi.I SOLDI SE LI FACCIANO DARE DAGLI STROZZINI DEL MERCATO E BASTA.

 

[DickSIM]

Ciao PIZZO!! guardiamo avanti...perchè indietro è tragico!!

un saluto a tutti.

 

[viralic]

Ciao PIZZO!! guardiamo avanti...perchè indietro è tragico!!

un saluto a tutti.

 

[guly]

oggi parla oil pallonaroche ***** di titolo.

 

[viralic]

oggi parla oil pallonaroche ***** di titolo.

Se non ti interessa e non ci credi e non ne hai cosa te ne importa ?

 

[guly]

ho un passato su questo cesso che mi autorizza ancora a far luce sulle falsita' passate e odierne.allora il tuo post MOLMED -10 CHE TITOLO?OLTRE CHE ERRATO MI DICI CHE LO HAI MESSO A FARE SE NON LE HAI?

 

[viralic]

forse non vi siete accorti di questo.....perdonati....anche il mercato non si è accorto di nulla !!! altri titoli avrebbero fatto +20%.....

Nicox: Vesneo, AC-170 On Track For NDA Submission In US - Quick Facts
6/3/2015 2:08 AM ET
Nicox S.A. (NICXF.PK,COX.PA), a French ophthalmic company, Wednesday announced that lead clinical candidates Vesneo and AC-170 are on track for New Drug Application or NDA submission in the United States.

In its update ahead of its Ordinary and Extraordinary Shareholder Meetings today, Nicox said that its licensee Bausch + Lomb, a unit of Valeant Pharmaceuticals International Inc. (VRX,VRX.TO) remains on track to submit an NDA to the US Food and Drug Administration or FDA for Vesneo (latanoprostene bunod). An announcement is expected once the NDA submission has been accepted for filing by the FDA, which normally takes place around 60 days following submission.

The NDA submission for AC-170, a novel formulation of cetirizine developed for the treatment of ocular itching associated with allergic conjunctivitis, also remains on track. Nicox's objective is to obtain FDA approval by the end of 2016.

Nicox noted that its advanced pipeline also features two pre-MAA (Marketing Authorization Application) candidates in Europe: AzaSite for bacterial conjunctivitis and BromSite for pain and inflammation after cataract surgery. Nicox now expects to submit European MAAs for both candidates by the end of the first half of 2016.


Based on the positive phase 3 results for Vesneo and increased interest in the potential of nitric oxide (NO)-donors in ophthalmology, Nicox's Board of Directors has selected NCX 470 as the Company's lead follow-on glaucoma candidate for internal development.

Nicox's research team will also continue to work on two other nitric oxide donor programs.

 

[guly]

forse non vi siete accorti di questo.....perdonati....anche il mercato non si è accorto di nulla !!! altri titoli avrebbero fatto +20%.....

Nicox: Vesneo, AC-170 On Track For NDA Submission In US - Quick Facts
6/3/2015 2:08 AM ET
Nicox S.A. (NICXF.PK,COX.PA), a French ophthalmic company, Wednesday announced that lead clinical candidates Vesneo and AC-170 are on track for New Drug Application or NDA submission in the United States.

In its update ahead of its Ordinary and Extraordinary Shareholder Meetings today, Nicox said that its licensee Bausch + Lomb, a unit of Valeant Pharmaceuticals International Inc. (VRX,VRX.TO) remains on track to submit an NDA to the US Food and Drug Administration or FDA for Vesneo (latanoprostene bunod). An announcement is expected once the NDA submission has been accepted for filing by the FDA, which normally takes place around 60 days following submission.

The NDA submission for AC-170, a novel formulation of cetirizine developed for the treatment of ocular itching associated with allergic conjunctivitis, also remains on track. Nicox's objective is to obtain FDA approval by the end of 2016.

Nicox noted that its advanced pipeline also features two pre-MAA (Marketing Authorization Application) candidates in Europe: AzaSite for bacterial conjunctivitis and BromSite for pain and inflammation after cataract surgery. Nicox now expects to submit European MAAs for both candidates by the end of the first half of 2016.


Based on the positive phase 3 results for Vesneo and increased interest in the potential of nitric oxide (NO)-donors in ophthalmology, Nicox's Board of Directors has selected NCX 470 as the Company's lead follow-on glaucoma candidate for internal development.

Nicox's research team will also continue to work on two other nitric oxide donor programs.

nenche vale la pena tradurlo in quanto e' la solita news senza importanza.IL MERCATO NON E' STUPIDO.SE NE ACCORGE E SA VALUTARE.ED E' CHIARO CHE E' UNA NEWS CHE VALE POCO.SE NO SALIVA,CAPISCONO MOLTO MEGLIO DI ME E DI TE,HANNO DEGLI ESPERTI IN MATERIA I FONDI E QUINDI LA NEWS L'AVRANNO SICURAMENTE VALUTATA.FATTENE UNA RAGIONE.

 

[guly]

forse non vi siete accorti di questo.....perdonati....anche il mercato non si è accorto di nulla !!! Altri titoli avrebbero fatto +20%.....

Nicox: Vesneo, ac-170 on track for nda submission in us - quick facts
6/3/2015 2:08 am et
nicox s.a. (nicxf.pk,cox.pa), a french ophthalmic company, wednesday announced that lead clinical candidates vesneo and ac-170 are on track for new drug application or nda submission in the united states.

In its update ahead of its ordinary and extraordinary shareholder meetings today, nicox said that its licensee bausch + lomb, a unit of valeant pharmaceuticals international inc. (vrx,vrx.to) remains on track to submit an nda to the us food and drug administration or fda for vesneo (latanoprostene bunod). An announcement is expected once the nda submission has been accepted for filing by the fda, which normally takes place around 60 days following submission.

The nda submission for ac-170, a novel formulation of cetirizine developed for the treatment of ocular itching associated with allergic conjunctivitis, also remains on track. Nicox's objective is to obtain fda approval by the end of 2016.

Nicox noted that its advanced pipeline also features two pre-maa (marketing authorization application) candidates in europe: Azasite for bacterial conjunctivitis and bromsite for pain and inflammation after cataract surgery. Nicox now expects to submit european maas for both candidates by the end of the first half of 2016.


Based on the positive phase 3 results for vesneo and increased interest in the potential of nitric oxide (no)-donors in ophthalmology, nicox's board of directors has selected ncx 470 as the company's lead follow-on glaucoma candidate for internal development.

Nicox's research team will also continue to work on two other nitric oxide donor programs.

gia' altri titoli avrebbero fatto + 20 e nicox no.e la ragione sarebbe?non si fidano?ha un ceo che fa ridere?oppure?

 

[viralic]

gia' altri titoli avrebbero fatto + 20 e nicox no.e la ragione sarebbe?non si fidano?ha un ceo che fa ridere?oppure?

Nicox ha comunicato in questa news( dovresti imparare l'inglese!) che è stata presentata da Valeant la nda per l'approvazione del vesneo....idem ha fatto poi Nicox per l'approvazione del farmaco di Aciex.....INSOMMA 2 richieste di approvazione contemporaneamente.
Ora la FDA ha 60 giorni di tempo per accettarle.
Valeant nel momento in cui FDA accetterà la nda farà una press release apposita.